Logo
x

Search

Subscribe Now

Agios

Agios Entered into an Exclusive Worldwide License Agreement with Alnylam for siRNA to Treat Polycythemia Vera

Agios Entered into an Exclusive Worldwide License Agreement with Alnylam for siRNA to Treat Polycythemia Vera

  • August 4, 2023
Agios’ Pyrukynd (mitapivat) Receives the EC’s Marketing Authorization for the Treatment of Pyruvate Kinase (PK) Deficiency

Agios’ Pyrukynd (mitapivat) Receives the EC’s Marketing Authorization for the Treatment of Pyruvate Kinase (PK) Deficiency

  • November 10, 2022
Agios’ Pyrukynd (mitapivat) Receives EMA's CHMP Positive Opinion Recommending the Marketing Authorization for the Treatment of PK Deficiency

Agios’ Pyrukynd (mitapivat) Receives EMA's CHMP Positive Opinion Recommending the Marketing Authorization for the Treatment of PK...

  • September 16, 2022
Agios Publishes P-III (ACTIVATE-T) Study Results of Pyrukynd (mitapivat) for Pyruvate Kinase Deficiency in The Lancet Haematology

Agios Publishes P-III (ACTIVATE-T) Study Results of Pyrukynd (mitapivat) for Pyruvate Kinase Deficiency in The Lancet Haematology

  • August 19, 2022
Agios Presents Results of Pyrukynd (mitapivat) in P-III (ACTIVATE) Study for the Treatment of PK Deficiency at EHA 2022

Agios Presents Results of Pyrukynd (mitapivat) in P-III (ACTIVATE) Study for the Treatment of PK Deficiency at EHA 2022

  • June 13, 2022
Agios’ Pyrukynd (mitapivat) Receives the US FDA’s Approval as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with PK Deficiency

Agios’ Pyrukynd (mitapivat) Receives the US FDA’s Approval as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with...

  • February 21, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.